心脏移植受者的COVID-19

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular and Thoracic Research Pub Date : 2022-01-01 DOI:10.34172/jcvtr.2022.31583

Sepideh Taghavi, Hoda Raffiei Jelodar, Ali Rafati, Nasim Naderi, Marzieh Mirtajaddini, Ahmad Amin, Leili Valizadeh, Razieh Omidvar, Monireh Kamali, Soroush Naseh

{"title":"心脏移植受者的COVID-19","authors":"Sepideh Taghavi, Hoda Raffiei Jelodar, Ali Rafati, Nasim Naderi, Marzieh Mirtajaddini, Ahmad Amin, Leili Valizadeh, Razieh Omidvar, Monireh Kamali, Soroush Naseh","doi":"10.34172/jcvtr.2022.31583","DOIUrl":null,"url":null,"abstract":"Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.","PeriodicalId":15207,"journal":{"name":"Journal of Cardiovascular and Thoracic Research","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871157/pdf/","citationCount":"8","resultStr":"{\"title\":\"COVID-19 in heart transplant recipients.\",\"authors\":\"Sepideh Taghavi, Hoda Raffiei Jelodar, Ali Rafati, Nasim Naderi, Marzieh Mirtajaddini, Ahmad Amin, Leili Valizadeh, Razieh Omidvar, Monireh Kamali, Soroush Naseh\",\"doi\":\"10.34172/jcvtr.2022.31583\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.\",\"PeriodicalId\":15207,\"journal\":{\"name\":\"Journal of Cardiovascular and Thoracic Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871157/pdf/\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiovascular and Thoracic Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/jcvtr.2022.31583\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular and Thoracic Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jcvtr.2022.31583","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 8

摘要

实体器官移植后，患者需要终身免疫抑制药物治疗，增加了对COVID-19的易感性。我们评估了COVID-19患者心脏移植受者的临床结果。方法:我们从2020年2月至2021年9月招募了22例COVID-19成人心脏移植病例。结果:患者最常见的症状为发热和肌痛。死亡3例(13.6%)。结论:尽管COVID-19合并急性排斥期心脏移植死亡率可能增加，但并非所有COVID-19心脏移植患者都需要减少免疫抑制剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COVID-19 in heart transplant recipients.

Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cardiovascular and Thoracic Research CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.00

自引率

0.00%

发文量

审稿时长

7 weeks